SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 424B5 - Prospectus [Rule 424(b)(5)]:
SEC Accession No. 0001104659-18-046992
Filing Date
2018-07-25
Accepted
2018-07-25 17:25:34
Documents
5

Document Format Files

Seq Description Document Type Size
1 424B5 a18-17513_5424b5.htm 424B5 1273268
2 GRAPHIC g175135cai001.jpg GRAPHIC 6478
3 GRAPHIC g175135ba01i001.jpg GRAPHIC 6804
4 GRAPHIC g175135bci001.jpg GRAPHIC 4000
5 GRAPHIC g175135ba03i001.jpg GRAPHIC 21975
  Complete submission text file 0001104659-18-046992.txt   1328994
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: 424B5 | Act: 33 | File No.: 333-223739 | Film No.: 18969451
SIC: 2834 Pharmaceutical Preparations